Letter: FibroTest for staging fibrosis in non-alcoholic fatty liver disease - authors' reply.

Festi D; Schiumerini R; Scaioli E; Colecchia A

doi:10.1111/apt.12228

Letter: FibroTest for staging fibrosis in non-alcoholic fatty liver disease - authors' reply.

Festi D, Schiumerini R, Scaioli E, Colecchia A

MeSH — NLM indexing Fatty Liver / diagnosis Humans

Actions du personnel

Télécharger le PDF

Les fichiers sont réservés à un usage autorisé dans les canaux partenaires BioPredictive.

Fibrotest Actitest Letter Independent Group Italy

Auteurs (4)

Citation

Festi D, Schiumerini R, Scaioli E, Colecchia A. Letter: FibroTest for staging fibrosis in non-alcoholic fatty liver disease - authors' reply. Aliment Pharmacol Ther. 2013;37(6):656-7. doi:10.1111/apt.12228.

Identifiants

DOI: 10.1111/apt.12228
PMID: 23406410

Tests

Maladies du foie

Atteintes hépatiques

Thèmes

Région

Panier

Votre panier est vide.

Parcourez les publications et utilisez Ajouter au panier sur n'importe quelle page de détail pour constituer une archive ZIP à envoyer aux clients.

Parcourir les publications

Letter: FibroTest for staging fibrosis in non-alcoholic fatty liver disease - authors' reply.

Autres publications de Festi D

Review article: the diagnosis of non-alcoholic fatty liver disease -- availability and accuracy of non-invasive methods.

Sur le même sujet

An Invisible Early Steatosis Phenotype Defined for a Large Population-Based Cohort.

Diagnostic performance of FibroTest-ActiTest, transient elastography, and the fibrosis-4 index in patients with autoimmune hepatitis using histological reference.

Metabolic dysfunction-associated steatotic liver disease (MASLD) biomarkers and progression of lower limb arterial calcification in patients with type 2 diabetes: a prospective cohort study.

Noninvasive Assessment of Liver Fibrosis.

Screening for Metabolic Dysfunction-Associated Steatotic Liver Disease-Related Advanced Fibrosis in Diabetology: A Prospective Multicenter Study.

Three Neglected STARD Criteria Reduce the Uncertainty of the Liver Fibrosis Biomarker FibroTest-T2D in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).